 ATLANTA--BUSINESS WIRE--Virios Therapeutics, Inc. the Company, a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, today announced the pricing of its initial public offering of 3,000,000 shares of its common stock at a public offering price of 10.00 per share, for gross proceeds of 30 million, before deducting underwriting discounts, commissions and offering expenses. In addition, the Compan 